Related Experiment Video
Updated: Mar 25, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Progress in pharmacogenetics: consortiums and new strategies
Drug Metabolism and Personalized Therapy
|February 26, 2016
Summary
Pharmacogenetics (PGx) advances personalized medicine by studying gene-drug interactions. Collaborative research and improved knowledge dissemination are key to translating PGx discoveries into clinical practice.
Area of Science:
- Pharmacogenomics and Personalized Medicine
Background:
- Pharmacogenetics (PGx) is crucial for personalized medicine (PM), focusing on how genes influence individual drug responses.
- The field necessitates large sample sizes, making collaborative consortia essential for progress.
- Challenges include translating research findings into clinical practice and standardizing methods.
Purpose of the Study:
- To review current progress in pharmacogenetics.
- To highlight the importance of genetic polymorphisms and detection strategies.
- To emphasize the need for knowledge dissemination and multidisciplinary approaches.
Main Methods:
- Review of current pharmacogenetics research and strategies.
- Examples illustrating the significance of polymorphisms and their detection.
- Discussion of collaborative efforts and technological advancements.
Main Results:
- Genomic high-throughput technologies are revolutionizing data generation for PGx.
- Identifying and replicating biomarker associations requires significant effort.
- Standardization and regulatory development are critical for clinical integration.
Conclusions:
- Collaborative consortia and advanced technologies are driving pharmacogenetics forward.
- Effective translation of PGx findings requires robust research, standardization, and knowledge sharing.
- A multidisciplinary approach is vital for improving clinician and patient understanding of PGx.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetics and Pharmacogenomics: Overview
137
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
137
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
108
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
01:27Pharmacogenetics of Drug Metabolism: Overview
106
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
106
01:27Principles of Pharmacogenetics: Types of Genetic Variants
87
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66